Medipharm Labs Corp Stock Analysis
| LABS Stock | CAD 0.07 0.01 7.69% |
Medipharm Labs Corp is overvalued with Real Value of 0.0641 and Hype Value of 0.07. The main objective of Medipharm Labs stock analysis is to determine its intrinsic value, which is an estimate of what Medipharm Labs Corp is worth, separate from its market price. There are two main types of Medipharm Labs' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Medipharm Labs' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Medipharm Labs' stock to identify patterns and trends that may indicate its future price movements.
The Medipharm Labs stock is traded in Canada on Toronto Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Canada. Medipharm Labs is usually not traded on Family Day, Good Friday, Victoria Day, Canada Day, Civic Holiday, Labour Day, Christmas Day, Boxing Day, New Year 's Day. Medipharm Stock trading window is adjusted to America/Toronto timezone.
Medipharm |
Medipharm Stock Analysis Notes
The company has price-to-book ratio of 0.67. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medipharm Labs Corp has Price/Earnings (P/E) ratio of 172.0. The entity recorded a loss per share of 0.02. The firm had not issued any dividends in recent years. Medipharm Labs had 1:2 split on the 4th of October 2018. MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates for derivative products in Canada and Australia. The company was founded in 2015 and is headquartered in Barrie, Canada. MEDIPHARM LABS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 230 people. To find out more about Medipharm Labs Corp contact David Pidduck at 705-719-7425 or learn more at https://www.medipharmlabs.com.Medipharm Labs Quarterly Total Revenue |
|
Medipharm Labs Corp Investment Alerts
| Medipharm Labs Corp generated a negative expected return over the last 90 days | |
| Medipharm Labs Corp has high historical volatility and very poor performance | |
| Medipharm Labs Corp has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 41.96 M. Net Loss for the year was (10.69 M) with profit before overhead, payroll, taxes, and interest of 14.8 M. | |
| Medipharm Labs Corp has accumulated about 24.14 M in cash with (4.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Advanced Equity Analysis - news.stocktradersdaily.com |
Medipharm Largest EPS Surprises
Earnings surprises can significantly impact Medipharm Labs' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-31 | 2022-12-31 | -0.01 | -0.02 | -0.01 | 100 | ||
2022-11-14 | 2022-09-30 | -0.02 | -0.03 | -0.01 | 50 | ||
2022-08-15 | 2022-06-30 | -0.02 | -0.03 | -0.01 | 50 |
Medipharm Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.06 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medipharm Labs's market, we take the total number of its shares issued and multiply it by Medipharm Labs's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Medipharm Profitablity
Medipharm Labs' profitability indicators refer to fundamental financial ratios that showcase Medipharm Labs' ability to generate income relative to its revenue or operating costs. If, let's say, Medipharm Labs is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Medipharm Labs' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Medipharm Labs' profitability requires more research than a typical breakdown of Medipharm Labs' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.17) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.04) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.04. | Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.25) | (0.26) |
Management Efficiency
Medipharm Labs Corp has return on total asset (ROA) of (0.0642) % which means that it has lost $0.0642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1605) %, meaning that it generated substantial loss on money invested by shareholders. Medipharm Labs' management efficiency ratios could be used to measure how well Medipharm Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of July 2025, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Medipharm Labs' Total Assets are very stable compared to the past year. As of the 20th of July 2025, Total Current Assets is likely to grow to about 50.2 M, while Net Tangible Assets are likely to drop about 59.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.11 | 0.10 | |
| Tangible Book Value Per Share | 0.10 | 0.10 | |
| Enterprise Value Over EBITDA | (1.75) | (1.84) | |
| Price Book Value Ratio | 0.57 | 0.54 | |
| Enterprise Value Multiple | (1.75) | (1.84) | |
| Price Fair Value | 0.57 | 0.54 | |
| Enterprise Value | 13.2 M | 12.5 M |
Leadership effectiveness at Medipharm Labs Corp is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Technical Drivers
As of the 20th of July, Medipharm Labs secures the Risk Adjusted Performance of (0.02), mean deviation of 3.41, and Standard Deviation of 5.24. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medipharm Labs Corp, as well as the relationship between them.Medipharm Labs Corp Price Movement Analysis
The output start index for this execution was eleven with a total number of output elements of fifty. The Simple Moving Average indicator is calculated by adding the closing price of Medipharm Labs for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Medipharm Labs Corp short-term fluctuations and highlight longer-term trends or cycles.
Medipharm Labs Outstanding Bonds
Medipharm Labs issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Medipharm Labs Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Medipharm bonds can be classified according to their maturity, which is the date when Medipharm Labs Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Medipharm Labs Predictive Daily Indicators
Medipharm Labs intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Medipharm Labs stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Medipharm Labs Forecast Models
Medipharm Labs' time-series forecasting models are one of many Medipharm Labs' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Medipharm Labs' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Medipharm Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Medipharm Labs prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Medipharm shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Medipharm Labs. By using and applying Medipharm Stock analysis, traders can create a robust methodology for identifying Medipharm entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.25) | (0.27) | |
| Operating Profit Margin | (0.26) | (0.27) | |
| Net Loss | (0.25) | (0.27) | |
| Gross Profit Margin | 0.31 | 0.32 |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Medipharm Labs to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
| All Next | Launch Module |
Other Information on Investing in Medipharm Stock
Medipharm Labs financial ratios help investors to determine whether Medipharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.